TOP GLOVE's 1QFY2020 results were above ours and consensus expectations due to low tax rate. Sequential earnings could be slightly lower due to the rising latex cost.
We raise our FY20-22E EPS by 10-13%, mainly to impute for the lower tax. Consequently, our Target Price is raised to MYR4.75 (+11%), on an unchanged 26x CY20F P/E (10% discount to our target P/E for Hartalega (HART MK, SELL, Target Price MYR4.95). Maintain HOLD.
Our preferred pick is Kossan (BUY, Target Price MYR4.85) for its exposure to the non-medical segment and undemanding CY20E P/E of 22x.
Above Expectations
Top Glove's 1QFY20 net profit of MYR111m (+39% q-o-q, +1% y-o-y) was 28%/26% of our and street’s full-year estimates. Results were above our expectation due to the low tax rate of 11% (vs. our assumption of 20%).
Given the available tax incentives, management has guided for its tax rate to be 13-15% in FY20F.
1QFY20: Stronger Q-o-q But Weaker Y-o-y
Q-o-q, 1QFY20 net profit rebounded (+39% q-o-q) on:
higher sales volume (+6% q-o-q) as the strong nitrile sales volume (+12% q-o-q) more than offset for the weaker latex powdered sales volume (-6% q-o-q);
higher EBITDA margin (+3.5-ppt q-o-q) on lower raw material costs (latex: -11% q-o-q, NBR: -2% q-o-q).
However, on a y-o-y basis, PBT was dragged by the weaker latex gloves given the structural demand shift to nitrile and competition. Additionally, the gross margin of latex gloves was around 2- ppt lower than that of nitrile.
Raise FY20-22F EPS by 10-13%
Some of its latex powdered lines have been converted to nitrile powdered lines. Coupled with the new capacity, nitrile is now its biggest revenue contributor (c.52% of total revenue).
We also note that it has reduced its planned new capacity for CY20 to 11.8b pcs p.a. (18.2b pcs p.a. previously), which may alleviate a potential supply overhang in 2020.
We raise our FY20-22F EPS by 13%/10%/10% as we:
lower our assumed tax rate to 13% (-7-ppt);
increase the sales volume of the higher margin nitrile gloves by 2% p.a.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....